Amphastar delivers back-to-back strong quarters as the company continues to see a rise in sales of its key products including Primatene Mist (epinephrine), glucagon and other epinephrine products. The company continues to build its pipeline and diversify its portfolio.

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.

Sales of Primatene Mist and other higher-margin products drive Amphastar's ifrst-quarter r5esults. The company continues to target a combined market worth around $10.5bn with seven generics in development.